Johnson & Johnson MedTech Hits $34B in 2025 Sales, Cardiovascular Up 15.8%
Johnson & Johnson’s MedTech segment reported $34 billion in 2025 sales, up 5.4% operationally, with cardiovascular revenues rising 15.8% to $8.9 billion following Abiomed and Shockwave acquisitions. J&J forecasts 2026 margins pressured by $500 million in tariffs and China VBP headwinds and plans a mid-2027 Orthopaedics spin-off.
1. 2025 MedTech Performance
J&J’s MedTech segment delivered $34 billion in 2025 sales, marking a 5.4% operational increase. Cardiovascular revenues surged 15.8% to $8.9 billion, driven by the 2022 Abiomed and 2024 Shockwave acquisitions.
2. Growth Drivers
Fifteen major product launches across orthopedics, surgery, cardiovascular and vision supported segment expansion. Electrophysiology improvements and momentum in Surgical Vision and wound closure also bolstered organic growth of 4.3%.
3. Headwinds and Margin Outlook
Sales in China remain under pressure from the volume-based procurement program, while potential tariffs of about $500 million are expected to weigh on 2026 margins. Competitive intensity in key MedTech markets is further challenging pricing power.
4. Future Outlook
J&J anticipates stronger 2026 growth through new product rollouts such as VARIPULSE, ETHICON4000 and OASYS MAX. A planned mid-2027 spin-off of its Orthopaedics franchise into DePuy Synthes aims to sharpen focus on high-growth MedTech markets.